Connectez-vous pour enregistrer et recevoir des mises à jour.
Qu'y a-t-il dans un nom ? Le dilemme du « vaccin » versus de la « thérapie » chez Moderna
Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”? That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccines against flus and emerging pathogens have been dashed by vaccine skeptics in…
Articles sources
MIT Technology Review (United States) | Apr 10, 2026
Your votes count
No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.
Traduit par IA · Voir l'original
The terminology surrounding mRNA treatments should be carefully considered to ensure clarity without alienating vaccine skeptics.
Traduit par IA · Voir l'original
The debate over terminology distracts from the urgent need for effective public health strategies amidst ongoing vaccine hesitancy.
Traduit par IA · Voir l'original
Emphasizing the therapeutic potential of mRNA technology could pave the way for more personalized and effective healthcare solutions.
Traduit par IA · Voir l'original
Labeling Moderna's treatment as a therapy undermines the public's trust in vaccines, complicating efforts to combat misinformation.
Traduit par IA · Voir l'original
Moderna's use of 'therapy' instead of 'vaccine' reflects a necessary evolution in how we understand and communicate medical innovations.
💡 How This Works
- • Add Statements: Post claims or questions (10-500 characters)
- • Vote: Agree, Disagree, or Unsure on each statement
- • Respond: Add detailed pro/con responses with evidence
- • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement
Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.
Support us